Canine Mast Cell Tumors: Grading, Staging, and the Integrative Edge

Learning Objectives

• 1Apply the Patnaik (3-tier) and Kiupel (2-tier) histopathologic grading systems to canine cutaneous mast cell tumors and explain why Kiupel is the primary driver of treatment decisions
• 2Interpret c-KIT mutation status (exon 11 ITD) and KIT IHC pattern as prognostic and predictive biomarkers for tyrosine kinase inhibitor response
• 3Select appropriate surgical margins based on Kiupel grade and explain the evidence base for 2 cm versus 3 cm lateral margins in low-to-intermediate grade MCT
• 4Identify indications for systemic therapy and compare toceranib (Palladia) and vinblastine-prednisone protocols including dosing, monitoring parameters, and dose modification triggers
• 5Construct an evidence-informed integrative oncology protocol for a canine MCT patient, including appropriate use of quercetin, omega-3 fatty acids, and turkey tail mushroom PSP with explicit evidence level ratings

Course Syllabus

1. 1
   Meet Maple — The Lump That Changes SizePreview

   module-1-meet-maple

   7 min
2. 2
   Grading and Staging — Two Systems, One Decision

   module-2-grading-staging

   8 min
3. 3
   Surgery — Margins Matter

   module-3-surgery-margins

   8 min